Phanes Therapeutics将在2026年ASCO年会上公布Spevatamig（PT886）联合化疗一线治疗转移性胰腺导管腺癌（PDAC）的2期临床试验更新结果-动脉网

Phanes Therapeutics to Present Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting

PR Newswire 等信源发布 2026-04-22 20:57



可切换为仅中文







SAN DIEGO

圣地亚哥

，

April 22, 2026

2026年4月22日

/PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will present updated Phase 2 results of spevatamig (PT886) in combination with chemotherapy in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) at the American Society of Clinical Oncology (ASCO) Annual Meeting held on May 29 – June 2, 2026 in Chicago.

/PRNewswire/ -- 临床阶段生物技术公司Phanes Therapeutics, Inc.（Phanes），专注于肿瘤学领域的创新药物发现与开发，宣布将在2026年5月29日至6月2日于芝加哥举行的美国临床肿瘤学会（ASCO）年会上，展示spevatamig（PT886）联合化疗在转移性胰腺导管腺癌（mPDAC）一线治疗中的二期更新结果。

Details of the presentation are below:.

陈述的细节如下：。

Title:

标题：

Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

Spevatamig（PT886），一种靶向Claudin 18.2（CLDN18.2）/CD47的双特异性抗体，联合吉西他滨和白蛋白结合型紫杉醇（GnP）用于转移性胰腺导管腺癌（mPDAC）的一线（1L）治疗。

Date/Time:

日期/时间：

May 30, 2026, 9:00 AM-12:00 PM CDT

2026年5月30日，上午9:00-12:00 中央夏令时间

Session:

会话：

Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary

胃肠道癌症 - 胃食管、胰腺和肝胆

Abstract #:

摘要编号：

4192

Poster #:

海报编号：

175

First Author:

第一作者：

Anwaar Saeed, MD, University of Pittsburgh Medical Center

安瓦尔·赛义德，医学博士，匹兹堡大学医学中心

ABOUT SPEVATAMIG

关于SPEVATAMIG

Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47. It was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA in 2022 and was granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024.

Spevatamig 是一种首创的类似天然 IgG 的双特异性抗体 (bsAb)，靶向 Claudin 18.2 和 CD47。它在 2022 年被 FDA 授予治疗胰腺癌的孤儿药资格 (ODD)，并在 2024 年被授予用于治疗转移性 Claudin 18.2 阳性胰腺腺癌患者的快速通道资格。

In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with pembrolizumab..

2023年，Phanes与默克（在美国和加拿大以外地区称为MSD）达成了一项临床合作协议，研究将spevatamig与pembrolizumab联合使用。

Phanes is conducting clinical trials with spevatamig in multiple cancer indications, including a Phase 2 study evaluating the efficacy of spevatamig in combination with chemotherapy in first-line PDAC patients. As of April 2026, 180 patients globally have been dosed with spevatamig collectively in monotherapy and combination therapy settings..

Phanes正在多种癌症适应症中进行spevatamig的临床试验，其中包括一项二期研究，评估spevatamig联合化疗在一线PDAC患者中的疗效。截至2026年4月，全球共有180名患者在单药治疗和联合治疗中接受了spevatamig的给药。

ABOUT PHANES THERAPEUTICS

关于普米斯生物治疗

Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase 2 clinical trials with spevatamig, peluntamig, and mavrostobart. Both spevatamig and peluntamig are first-in-class bispecific antibodies and have been granted orphan drug and Fast Track designations by the FDA..

Phanes Therapeutics, Inc. 是一家临床阶段的生物技术公司，专注于肿瘤学领域的创新药物发现与开发。目前，该公司正在进行三项二期临床试验，涉及药物包括spevatamig、peluntamig和mavrostobart。其中，spevatamig和peluntamig均为首创的双特异性抗体，并已获得美国食品药品监督管理局（FDA）授予的孤儿药资格和快速通道资格。

The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody

公司通过利用其专有的技术平台（如PACbody）建立了强大的产品线。

, SPECpair

SPECpair

and ATACCbody

和ATACCbody

to develop novel biologics that address high unmet medical needs in cancer.

开发满足癌症领域高度未满足医疗需求的新型生物制剂。

For more information about Phanes Therapeutics, please visit

有关Phanes Therapeutics的更多信息，请访问

www.phanesthera.com

。